KACIE DAVIS: Open Payments
NPI 1972970747 · DOTHAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,668 in 99 payments from 22 companies in 2025. Trend: 2023 $1,534 · 2024 $1,710 · 2025 $1,668
Food & beverage: $1,668
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $259 |
| Lilly USA, LLC | 14 | $184 |
| AstraZeneca Pharmaceuticals LP | 10 | $166 |
| Amgen Inc. | 13 | $156 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $150 |
| Novo Nordisk Inc | 6 | $84 |
| PFIZER INC. | 5 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $73 |
| Tandem Diabetes Care, Inc. | 3 | $71 |
| GlaxoSmithKline, LLC. | 4 | $67 |
Products named: MOUNJARO, Kerendia, REPATHA, AIRSUPRA, REXULTI, NURTEC ODT, QULIPTA, FANAPT.
Industry payments across AL — which companies pay providers there.
